Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Analysts at Chardan Capital raised their FY2025 EPS estimates for shares of Unity Biotechnology in a research report issued to clients and investors on Monday, March 10th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($0.72) per share for the year, up from their prior estimate of ($0.74). Chardan Capital currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Unity Biotechnology in a report on Monday, March 10th.
Unity Biotechnology Trading Down 1.1 %
NASDAQ:UBX opened at $1.77 on Thursday. The stock has a market capitalization of $29.86 million, a PE ratio of -1.35 and a beta of 1.02. The firm’s 50 day moving average is $1.90 and its 200 day moving average is $1.51. Unity Biotechnology has a 12 month low of $0.94 and a 12 month high of $3.10.
Institutional Investors Weigh In On Unity Biotechnology
A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC raised its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 29.49% of the stock is owned by institutional investors and hedge funds.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Further Reading
- Five stocks we like better than Unity Biotechnology
- Why Invest in 5G? How to Invest in 5G Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Overbought Stocks Explained: Should You Trade Them?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
